UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032122
Receipt number R000036648
Scientific Title Suppressive effect of Supplement on the postprandial blood glucose level -A randomized, double blind, placebo controlled, cross-over study-
Date of disclosure of the study information 2018/04/05
Last modified on 2018/05/22 13:48:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Suppressive effect of Supplement on the postprandial blood glucose level -A randomized, double blind, placebo controlled, cross-over study-

Acronym

Suppressive effect of Supplement on the postprandial blood glucose level

Scientific Title

Suppressive effect of Supplement on the postprandial blood glucose level -A randomized, double blind, placebo controlled, cross-over study-

Scientific Title:Acronym

Suppressive effect of Supplement on the postprandial blood glucose level

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of test food on the postprandial blood glucose level of subjects

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

AUC for postprandial blood glucose level

Key secondary outcomes

・AUC for insulin level
・Postprandial blood glucose levels and insulin levels of 30, 60, 90, and 120 minutes after sucrose ingestion
・Cmax for blood glucose level


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Intake of test food, and then ingestion of placebo after wash out period

Interventions/Control_2

Intake of placebo, and then ingestion of test food after wash out period

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1)Males and females 20 to 64 years of age
2)Subjects whose fasting blood glucose levels are less than 126 mg/dL.
3)Subjects whose postprandial blood glucose levels on 120 minutes after 75g sucrose ingestion are less than 200 mg/dL.

Key exclusion criteria

1)Subjects who have serious medical history and history of surgical resection of the gastrointestinal tract excluding appendectomy
2)Subjects whose HbA1c(NGSP) are more than 6.5%
3) Subjects who routinely use medicine, supplements, FOSHU, and/or health food which affect to result of the study.
4) Subjects who have allergy to test food and/or high fat meal and have diarrhea.
5) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating.
6) Heavy user of alcohol or excessive smokers
7) Subjects who are judged inappropriate for participation in this study by the investigator

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuhiko Takano

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital

Division name

clinical pharmacology center

Zip code


Address

61-1 Sin-ei, Kiyota-ku, Sapporo, Hokkaido 004-0839, Japan

TEL

011-882-0111

Email

takano@ughp-cpc.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaya Tsubokawa

Organization

FANCL Corporation

Division name

Research Institute

Zip code


Address

12-13 Kamishinano, Totsuka-ku, Yokohama, Kanagawa, Japan

TEL

045-820-3569

Homepage URL


Email

tsubokawa_masaya@fancl.co.jp


Sponsor or person

Institute

FANCL Corporation

Institute

Department

Personal name



Funding Source

Organization

FANCL Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人北武会美しが丘病院


Other administrative information

Date of disclosure of the study information

2018 Year 04 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 03 Month 09 Day

Date of IRB


Anticipated trial start date

2018 Year 04 Month 02 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 04 Month 05 Day

Last modified on

2018 Year 05 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036648


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name